Quality of Anticoagulation Control in Preventing Adverse Events in Patients with Heart Failure in Sinus Rhythm: Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction Trial Substudy

Shunichi Homma, John L P Thompson, Min Qian, Siqin Ye, Marco R. Di Tullio, Gregory Y H Lip, Douglas L. Mann, Ralph L Sacco, Bruce Levin, Patrick M. Pullicino, Ronald S. Freudenberger, John R. Teerlink, Susan Graham, J. P. Mohr, Arthur J. Labovitz, Richard Buchsbaum, Conrado J. Estol, Dirk J. Lok, Piotr Ponikowski, Stefan D. Anker

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background-The aim of this study is to examine the relationship between time in the therapeutic range (TTR) and clinical outcomes in heart failure patients in sinus rhythm treated with warfarin. Methods and Results-We used data from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial to assess the relationship of TTR with the WARCEF primary outcome (ischemic stroke, intracerebral hemorrhage, or death), with death alone, ischemic stroke alone, major hemorrhage alone, and net clinical benefit (primary outcome and major hemorrhage combined). Multivariable Cox models were used to examine how the event risk changed with TTR and to compare the high TTR, low TTR, and aspirin-treated patients, with TTR being treated as a time-dependent covariate. A total of 2217 patients were included in the analyses; among whom 1067 were randomized to warfarin and 1150 were randomized to aspirin. The median (interquartile range) follow-up duration was 3.6 (2.0-5.0) years. Mean (±SD) age was 61±11.3 years, with 80% being men. The mean (±SD) TTR was 57% (±28.5%). Increasing TTR was significantly associated with reduction in primary outcome (adjusted P

Original languageEnglish (US)
Pages (from-to)504-509
Number of pages6
JournalCirculation: Heart Failure
Volume8
Issue number3
DOIs
StatePublished - May 4 2015

Fingerprint

Warfarin
Quality Control
Aspirin
Heart Failure
Therapeutics
Stroke
Hemorrhage
Cerebral Hemorrhage
Proportional Hazards Models

Keywords

  • anticoagulant
  • heart failure
  • hemorrhage
  • stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Quality of Anticoagulation Control in Preventing Adverse Events in Patients with Heart Failure in Sinus Rhythm : Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction Trial Substudy. / Homma, Shunichi; Thompson, John L P; Qian, Min; Ye, Siqin; Di Tullio, Marco R.; Lip, Gregory Y H; Mann, Douglas L.; Sacco, Ralph L; Levin, Bruce; Pullicino, Patrick M.; Freudenberger, Ronald S.; Teerlink, John R.; Graham, Susan; Mohr, J. P.; Labovitz, Arthur J.; Buchsbaum, Richard; Estol, Conrado J.; Lok, Dirk J.; Ponikowski, Piotr; Anker, Stefan D.

In: Circulation: Heart Failure, Vol. 8, No. 3, 04.05.2015, p. 504-509.

Research output: Contribution to journalArticle

Homma, S, Thompson, JLP, Qian, M, Ye, S, Di Tullio, MR, Lip, GYH, Mann, DL, Sacco, RL, Levin, B, Pullicino, PM, Freudenberger, RS, Teerlink, JR, Graham, S, Mohr, JP, Labovitz, AJ, Buchsbaum, R, Estol, CJ, Lok, DJ, Ponikowski, P & Anker, SD 2015, 'Quality of Anticoagulation Control in Preventing Adverse Events in Patients with Heart Failure in Sinus Rhythm: Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction Trial Substudy', Circulation: Heart Failure, vol. 8, no. 3, pp. 504-509. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001725
Homma, Shunichi ; Thompson, John L P ; Qian, Min ; Ye, Siqin ; Di Tullio, Marco R. ; Lip, Gregory Y H ; Mann, Douglas L. ; Sacco, Ralph L ; Levin, Bruce ; Pullicino, Patrick M. ; Freudenberger, Ronald S. ; Teerlink, John R. ; Graham, Susan ; Mohr, J. P. ; Labovitz, Arthur J. ; Buchsbaum, Richard ; Estol, Conrado J. ; Lok, Dirk J. ; Ponikowski, Piotr ; Anker, Stefan D. / Quality of Anticoagulation Control in Preventing Adverse Events in Patients with Heart Failure in Sinus Rhythm : Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction Trial Substudy. In: Circulation: Heart Failure. 2015 ; Vol. 8, No. 3. pp. 504-509.
@article{415dde71ba7043bb96c812994513d2d6,
title = "Quality of Anticoagulation Control in Preventing Adverse Events in Patients with Heart Failure in Sinus Rhythm: Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction Trial Substudy",
abstract = "Background-The aim of this study is to examine the relationship between time in the therapeutic range (TTR) and clinical outcomes in heart failure patients in sinus rhythm treated with warfarin. Methods and Results-We used data from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial to assess the relationship of TTR with the WARCEF primary outcome (ischemic stroke, intracerebral hemorrhage, or death), with death alone, ischemic stroke alone, major hemorrhage alone, and net clinical benefit (primary outcome and major hemorrhage combined). Multivariable Cox models were used to examine how the event risk changed with TTR and to compare the high TTR, low TTR, and aspirin-treated patients, with TTR being treated as a time-dependent covariate. A total of 2217 patients were included in the analyses; among whom 1067 were randomized to warfarin and 1150 were randomized to aspirin. The median (interquartile range) follow-up duration was 3.6 (2.0-5.0) years. Mean (±SD) age was 61±11.3 years, with 80{\%} being men. The mean (±SD) TTR was 57{\%} (±28.5{\%}). Increasing TTR was significantly associated with reduction in primary outcome (adjusted P",
keywords = "anticoagulant, heart failure, hemorrhage, stroke",
author = "Shunichi Homma and Thompson, {John L P} and Min Qian and Siqin Ye and {Di Tullio}, {Marco R.} and Lip, {Gregory Y H} and Mann, {Douglas L.} and Sacco, {Ralph L} and Bruce Levin and Pullicino, {Patrick M.} and Freudenberger, {Ronald S.} and Teerlink, {John R.} and Susan Graham and Mohr, {J. P.} and Labovitz, {Arthur J.} and Richard Buchsbaum and Estol, {Conrado J.} and Lok, {Dirk J.} and Piotr Ponikowski and Anker, {Stefan D.}",
year = "2015",
month = "5",
day = "4",
doi = "10.1161/CIRCHEARTFAILURE.114.001725",
language = "English (US)",
volume = "8",
pages = "504--509",
journal = "Circulation. Heart failure",
issn = "1941-3297",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Quality of Anticoagulation Control in Preventing Adverse Events in Patients with Heart Failure in Sinus Rhythm

T2 - Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction Trial Substudy

AU - Homma, Shunichi

AU - Thompson, John L P

AU - Qian, Min

AU - Ye, Siqin

AU - Di Tullio, Marco R.

AU - Lip, Gregory Y H

AU - Mann, Douglas L.

AU - Sacco, Ralph L

AU - Levin, Bruce

AU - Pullicino, Patrick M.

AU - Freudenberger, Ronald S.

AU - Teerlink, John R.

AU - Graham, Susan

AU - Mohr, J. P.

AU - Labovitz, Arthur J.

AU - Buchsbaum, Richard

AU - Estol, Conrado J.

AU - Lok, Dirk J.

AU - Ponikowski, Piotr

AU - Anker, Stefan D.

PY - 2015/5/4

Y1 - 2015/5/4

N2 - Background-The aim of this study is to examine the relationship between time in the therapeutic range (TTR) and clinical outcomes in heart failure patients in sinus rhythm treated with warfarin. Methods and Results-We used data from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial to assess the relationship of TTR with the WARCEF primary outcome (ischemic stroke, intracerebral hemorrhage, or death), with death alone, ischemic stroke alone, major hemorrhage alone, and net clinical benefit (primary outcome and major hemorrhage combined). Multivariable Cox models were used to examine how the event risk changed with TTR and to compare the high TTR, low TTR, and aspirin-treated patients, with TTR being treated as a time-dependent covariate. A total of 2217 patients were included in the analyses; among whom 1067 were randomized to warfarin and 1150 were randomized to aspirin. The median (interquartile range) follow-up duration was 3.6 (2.0-5.0) years. Mean (±SD) age was 61±11.3 years, with 80% being men. The mean (±SD) TTR was 57% (±28.5%). Increasing TTR was significantly associated with reduction in primary outcome (adjusted P

AB - Background-The aim of this study is to examine the relationship between time in the therapeutic range (TTR) and clinical outcomes in heart failure patients in sinus rhythm treated with warfarin. Methods and Results-We used data from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial to assess the relationship of TTR with the WARCEF primary outcome (ischemic stroke, intracerebral hemorrhage, or death), with death alone, ischemic stroke alone, major hemorrhage alone, and net clinical benefit (primary outcome and major hemorrhage combined). Multivariable Cox models were used to examine how the event risk changed with TTR and to compare the high TTR, low TTR, and aspirin-treated patients, with TTR being treated as a time-dependent covariate. A total of 2217 patients were included in the analyses; among whom 1067 were randomized to warfarin and 1150 were randomized to aspirin. The median (interquartile range) follow-up duration was 3.6 (2.0-5.0) years. Mean (±SD) age was 61±11.3 years, with 80% being men. The mean (±SD) TTR was 57% (±28.5%). Increasing TTR was significantly associated with reduction in primary outcome (adjusted P

KW - anticoagulant

KW - heart failure

KW - hemorrhage

KW - stroke

UR - http://www.scopus.com/inward/record.url?scp=84942937011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942937011&partnerID=8YFLogxK

U2 - 10.1161/CIRCHEARTFAILURE.114.001725

DO - 10.1161/CIRCHEARTFAILURE.114.001725

M3 - Article

C2 - 25850425

AN - SCOPUS:84942937011

VL - 8

SP - 504

EP - 509

JO - Circulation. Heart failure

JF - Circulation. Heart failure

SN - 1941-3297

IS - 3

ER -